MOG and myeloid sarcoma: Our study helps to advance knowledge regarding potential etiologies underlying inflammatory myelopathies in patients who are seronegative for both AQP4-IgG and MOG-IgG (“double-seronegative”), without characteristics typical for MS or other well-established neuroimmune disorders.